Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, completed its $52M Series A financing round. Rock Springs Capital led the round. Several other investors participated, including funds and accounts advised by T. Rowe Price Associates, Inc., Seed-round lead investor Andreessen Horowitz, Menlo Ventures, and Radical Ventures.

The Series A round had further participation by Felicis Ventures (also invested in the seed round), Jazz Venture Partners, Harpoon Ventures, Ulu Ventures, Mark Leslie (former CEO of Veritas Software), Jeffrey Rothschild (co-founder of Veritas Software; early employee, VP of Infrastructure Engineering at Facebook), Propagator Ventures, and Open Field Capital.

Genesis has developed Dynamic PotentialNet and other novel neural network algorithms that examine drug-target complexes as flexible, spatial graphs- enabling superior prediction of potency and selectivity of drug candidates. The company's technology offers significant advantages in addressing novel, previously undruggable targets in addition to well-characterized therapeutic targets.